Investor World Review: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Investor World Review.

November 2025

Mo	Tu	We	Th	Fr	Sa	Su
					1	2
3	4	5	6	7	8	9
10	11	12	13	14	15	16
17	18	19	20	21	22	23
24	25	26	27	28	29	30

December 2025

Mo	Tu	We	Th	Fr	Sa	Su
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30	31

January 2026

Mo	Tu	We	Th	Fr	Sa	Su
			1	2	3	4
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30	31

Press releases published on December 7, 2025

December 7, 2025

Same Day Garage Door, LLC Introduces Garage Door Replacement Program to Support Lima, OH Homes During Peak Winter Season

EIN Presswire

December 7, 2025

URS Invests in Yellow Visa, acquiring 40% Stake to Accelerate AI-Driven Immigration Automation

EIN Presswire

December 7, 2025

Global Immigration Partners PLLC Unveils In-Depth Report on EB-5 Investment Risks and How to Evaluate a Safe Project

EIN Presswire

December 7, 2025

COGNNA announces a $9.2M Series A led by Impact46 with participation from BNVTCapital, VisionVentures, and TaliVentures.

EIN Presswire

December 7, 2025

Disruptive Futures Institute Names Metaruptions 2026 Word of the Year & Launches Roger Spitz’s Visionary Keynote Series

EIN Presswire

December 7, 2025

Payment as a Service Market Expected to Reach $53.6 Billion by 2031 | 21.4% CAGR Outlook

EIN Presswire

December 7, 2025

Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire

$At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis$

December 7, 2025

At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

GlobeNewswire

$SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025$

December 7, 2025

SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025

GlobeNewswire

December 7, 2025

Drilling hits wide zone of mineralisation in new area well outside resource

GlobeNewswire

December 7, 2025

Les forages recoupent une large zone minéralisée dans un nouveau secteur bien en dehors des ressources

GlobeNewswire

December 7, 2025

Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition

GlobeNewswire

December 7, 2025

Lynozyfic™ (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment

GlobeNewswire

December 7, 2025

CAPHRA Raises Alarm over Legitimacy of WHO Tobacco Treaty.

GlobeNewswire

December 7, 2025

MRX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Marex Group plc Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

GlobeNewswire

December 7, 2025

Dyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy; Tomorrow, December 8 at 8:00 a.m. ET

GlobeNewswire

December 7, 2025

Nayax Considering an Offering of Notes and Warrants in Israel

GlobeNewswire

December 7, 2025

Pinta Miami Acquisitions, Awards, and Highlights

EIN Presswire

December 7, 2025

Joseph Stone Capital Celebrates 12 Years of Client Success, Transparency, and Excellence

EIN Presswire

December 7, 2025

Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease

GlobeNewswire